London · Delayed Price · Currency is GBP · Price in USD Arrowhead Pharmaceuticals Company Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
The company’s product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency.
It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B.
In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials.
Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial.
Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No.
3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 609 |
| CEO | Christopher Anzalone |
Contact Details
Address: 177 East Colorado Boulevard Pasadena, Delaware 91105 United States | |
| Phone | 626 304 3400 |
| Website | arrowheadpharma.com |
Stock Details
| Ticker Symbol | 0HI3 |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| ISIN Number | US04280A1007 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher R. Anzalone Ph.D. | Chairman, Chief Executive Officer and President |
| Patrick O'Brien J.D., PharmD | Chief Operating Officer, General Counsel and Secretary |
| Dr. James C. Hamilton M.D., MBA | Chief Medical Officer and Head of Research & Development |
| Dr. Mark M. Davis Ph.D. | Founder and Founder and Director of Insert Therapeutics Inc & Calando |
| Daniel J. Apel | Chief Financial Officer |
| Dr. Vincent Anzalone CFA | Head of Investor Relations and Vice President |
| Howard Lovy | Director of Communications |
| Dr. Bruce D. Given M.D. | Chief Medical Scientist |
| Dr. Mark Seefeld | Head of Toxicology and Vice President |
| Aaron Tan | Head of Tax |